Ketamine-Assisted Psychotherapy Training in Canada (2026 Guide)

Ketamine-assisted psychotherapy (KAT) training prepares licensed Canadian clinicians to deliver structured therapy with sub-anaesthetic ketamine across intramuscular, sublingual, oral, intranasal, and intravenous routes. This guide covers who can train, what the curriculum includes, the provincial regulatory rules every clinician must understand, the peer-reviewed evidence base, certification and continuing-education credits, and how ATMA CENA's pathways prepare clinicians for safe and accountable practice.

Key takeaways

• Ketamine is a Health Canada-approved anaesthetic; its use for psychiatric indications is off-label and governed by provincial physician colleges. Health Canada's Special Access Program does not apply to ketamine.
• Provincial regulatory frameworks vary materially. Alberta (CPSA, March 2026), Manitoba (CPSM, January 2026), and British Columbia (CPSBC, August 2025 interim) have current published guidance. Ontario (CPSO) has no ketamine-specific policy as of May 2026.
• The peer-reviewed evidence base for ketamine in treatment-resistant depression is substantial. The combination of ketamine with structured psychotherapy — referred to as KAP (ketamine-assisted psychotherapy) or KAT — is supported by multiple observational studies including Canadian community programs.
• Training is open to physicians, nurse practitioners, registered psychologists, registered psychotherapists, registered counsellors, registered nurses, and registered social workers, with scope-of-practice limits per profession and province.
• ATMA CENA's pathways anchor on the Psychedelic-Assisted Therapy Foundations course (14 hours) and add advanced courses, supervised learning labs, and an optional Ketamine-Assisted Therapy Immersive Experience.

What is ketamine-assisted psychotherapy training?

Ketamine-assisted psychotherapy training prepares a licensed mental-health clinician to deliver structured therapy in conjunction with sub-anaesthetic ketamine administration. The training covers preparation sessions before any medicine is given, supervised dosing-day skills with attention to set and setting, integration psychotherapy in the days and weeks afterward, screening and contraindication assessment, route-of-administration competencies, and the provincial regulatory framework that governs off-label ketamine prescribing in Canada.

KAT differs from ketamine infusion alone. The medicine is not the treatment in isolation. A systematic narrative review of 17 KAP studies (603 participants) identified preparation, supported facilitation during the medicine session, and structured post-session integration as the three psychotherapy components most consistently associated with sustained outcomes [Drozdz et al. 2022]. Training programs vary in how they teach these three components and in how much supervised practice they require before independent practice.

ATMA CENA's KAT-relevant training sits inside the broader psychedelic-assisted therapy training program and runs across all three pathways: Clinical for non-prescribing therapists, Prescriber for physicians and nurse practitioners, and Integrative (Essentials) for clinicians whose role focuses on preparation and integration support.

Who can train in KAT? Eligibility by profession and province

Atomic answer: KAT training is open to a range of regulated mental-health clinicians, but scope of practice for the medicine itself differs by profession and province. Only physicians and nurse practitioners with appropriate prescribing authority may prescribe and administer ketamine. Registered psychologists, registered psychotherapists (Ontario), permit-holding psychotherapists (Quebec), registered counsellors, registered nurses, and registered social workers can deliver the psychotherapy components of KAT and can serve on a multidisciplinary team under prescriber oversight, but they cannot prescribe or independently administer the medicine. Restricted titles (such as psychologist, Registered Psychotherapist, and psychothérapeute) apply only to clinicians registered with the relevant provincial college.

Additional context applies for clinicians wanting to advertise services. Ontario's CRPO Standard 6.2 prohibits use of client testimonials in advertising and bans superlatives or outcome promises; Alberta's CAP Practice Guideline on Professional Communications has parallel rules. Training does not change advertising standards.

For role-specific deeper dives, see the dedicated pages for training for physicians, counsellors, psychotherapists, and psychologists.

Understanding administration routes: IV, IM, sublingual, oral, and intranasal

Route of administration matters for training scope, regulatory requirements, and clinical experience. Different routes have different pharmacokinetics, supervision requirements, facility infrastructure needs, and provincial-college rules.

• Intravenous (IV) ketamine produces rapid onset and predictable plasma levels. IV administration in a non-hospital setting requires accredited medical-facility status in every Canadian province that has addressed this (Alberta CPSA-accredited facility; Manitoba CPSM-accredited non-hospital facility; BC CPSBC NHMSFAP framework; Saskatchewan accredited non-hospital treatment facility) [CPSA 2026; CPSM 2026; CPSBC 2025]. IV is the most evidence-rich route for treatment-resistant depression in the peer-reviewed literature.
• Intramuscular (IM) ketamine is widely used in KAP practice, including in the Canadian Roots to Thrive group model in BC where 49 percent of sessions documented transient elevated post-session blood pressure that resolved without intervention [Tsang et al. 2023]. CPSA Alberta permits IM in community settings with appropriate prescriber competency.
• Sublingual (SL) and oral ketamine support cost-effective maintenance after acute IV induction in some Canadian programs. The Edmonton public-hospital community ketamine program describes a step-down model using SL or intranasal ketamine following IV induction to improve sustainable access [Chrenek, Duong, Swainson et al. 2024].
• Intranasal racemic ketamine is used in some KAP protocols. Intranasal esketamine (Spravato®) is separately approved by Health Canada for treatment-resistant major depressive disorder in adults in combination with an oral antidepressant. Spravato is available only through the manufacturer's Janssen Journey™ Program and, per CPSBC's August 2025 clarification, may be prescribed by psychiatrists in community settings with appropriate training.

ATMA CENA's Applied Clinical Practice in Psychedelic Therapy and Prescribing & Oversight in Psychedelic-Assisted Therapy courses include route-specific protocols. The optional Ketamine-Assisted Therapy Immersive Experience provides in-person practicum exposure.

What KAT training covers: core curriculum components

A comprehensive KAT curriculum covers screening and contraindication assessment, preparation psychotherapy, dosing-day session structure and facilitation, vital-sign monitoring and adverse-event response, integration psychotherapy, ethics and informed consent, documentation, the Canadian regulatory framework, and post-treatment continuity-of-care.

The first published competency framework for psychedelic therapist training identifies six core competencies relevant to KAT clinicians: empathetic abiding presence, trust enhancement, spiritual intelligence, knowledge of physical and psychological effects, self-awareness and ethical integrity, and proficiency in complementary techniques [Phelps 2017]. These layer on top of the clinician's existing licensure rather than replacing core therapy skills.

ATMA CENA's KAT-relevant courses are structured as follows:

• Psychedelic-Assisted Therapy Foundations — the 14-hour prerequisite course covering history, neurobiology, ethics, set and setting, and Canadian regulatory landscape.
• Applied Clinical Practice in Psychedelic Therapy — 55 hours of advanced curriculum for the Clinical pathway including a KAT module covering ketamine overview, mock KAT sessions, and clinical process, ethics, and integration.
• Prescribing & Oversight in Psychedelic-Assisted Therapy — 40-hour prescriber course covering ketamine pharmacology, dosing, screening, oversight, and SAP application authorship for psilocybin and MDMA where relevant.
• Advanced Safety & Support Practices in Psychedelic-Assisted Therapy — 39-hour Integrative-pathway course covering preparation and integration support roles including KAT context.

Reviewing the broader Canadian KAT training market: TheraPsil's prescriber masterclass for psilocybin offers 8 Mainpro+ credits but does not address ketamine. Numinus's Practical Applications of Ketamine-Assisted Therapy course is approved for 50 CE hours by CCPA and OPQ and 3 CE hours by CPA. Roots to Thrive's Experiential KAT Training in Nanaimo offers 52 hours but is not formally CE-accredited. Field Trip Health's PAT training is not currently accredited [verified May 2026].

Experiential training and live supervision

Atomic answer: Experiential training and live supervision are the components of KAT preparation that didactic study cannot replace. A qualitative study of eight Numinus-trained clinicians in Canada and the United States documented unanimous agreement that formal experiential training is a critical missing element in current KAT training programs [Argento et al. 2024]. Health Canada's December 2022 expectations for clinical trials state that during the dosing phase a minimum of two therapists must be present and that any unlicensed members of the therapy team must work under direct supervision of a licensed therapist [Health Canada 2022]. ATMA CENA's training combines online didactic delivery, the Supervised Learning Lab for small-group live skills practice, and the optional in-person Ketamine-Assisted Therapy Immersive Experience for hands-on exposure to the full arc of a KAT session.

Personal experiential exposure to non-ordinary states is an active discussion in the field. A peer-reviewed argumentative review in Psychedelic Medicine contends that "firsthand subjective experience of PaT is a crucial training element for PaT practitioners" [Dames et al. 2024]. Health Canada SAP protocols do not mandate personal psychedelic experience as a training prerequisite. Different programs make different choices on this question; the choice carries professional, ethical, and regulatory considerations that clinicians should evaluate before opting into experiential components.

Prescriber track: training for physicians and nurse practitioners

Physicians (including psychiatrists, family physicians, and emergency physicians) and nurse practitioners with controlled-substance prescribing authority hold the unique professional capacity to prescribe ketamine, lead medical screening, and serve as medical director for KAT delivery. ATMA CENA's Prescriber Pathway is designed for this audience.

Provincial-college guidance is the operative training framework for prescribers:

• Alberta — CPSA's Ketamine prescribing, administration and oversight expectations (March 2026) is the current authority. CPSA's psychedelic-assisted-psychotherapy facility-accreditation standards apply for PAPT delivery: "This therapy must be provided within a CPSA-accredited medical facility by a psychiatrist or a physician in consultation with a psychiatrist" [CPSA 2026].
• Manitoba — CPSM's Ketamine: What Prescribers and Pharmacists Need to Know (January 20, 2026) emphasizes prescriber competency, DPIN review, and accredited facilities for IV administration [CPSM 2026].
• British Columbia — CPSBC's Interim Guidance on Ketamine Administration via IM, Oral, SL, IN Routes (Version 1.3, August 11, 2025) covers non-IV routes in community settings; informed consent for off-label use is emphasized [CPSBC 2025].
• Ontario — CPSO has not published a ketamine-specific policy. Off-label use falls under the general Prescribing Drugs policy and the Complementary and Alternative Medicine policy. Prescribers must demonstrate adequate knowledge, skill, and judgment.
• Quebec — INESSS's May 2025 clinical opinion on parenteral ketamine for treatment-resistant depression is the most recent institutional guidance and supports parenteral KAT within a defined framework [INESSS 2025].

Safety, screening, and risk management in KAT practice

Ketamine has a well-documented safety profile in supervised clinical contexts. A systematic review of 93 ketamine trials (3,756 participants) found an incidence of serious medical adverse events of approximately 0.1 percent and zero serious cardiac or cerebrovascular events under screened conditions [Hovda et al. 2024]. Cardiovascular stimulation, including transient hypertension and tachycardia, is common during dosing and resolves without intervention in most cases [Tsang et al. 2023]. Dissociative reactions are the most prominent acute adverse effect and typically resolve within 1.5 hours after the dose [Popova et al. 2019].

Long-term bladder safety (ketamine-associated uropathy) is documented predominantly in heavy recreational users. A meta-analysis of 45 articles (4,921 patients) on ketamine-associated uropathy found that hydronephrosis occurred in approximately 30 percent of cases — almost exclusively in chronic high-dose recreational users; ketamine abstinence is required for recovery [Chan et al. 2022]. Evidence for clinically dosed therapeutic ketamine causing cystitis is limited to rare case reports.

Training programs must teach screening and contraindication assessment for cardiovascular risk (uncontrolled hypertension, unstable angina, raised intracranial pressure, recent myocardial infarction); psychiatric risks (active psychosis, mania, certain dissociative disorders); pregnancy; and concurrent medications (notably MAOIs, certain CYP3A4 interactions). Standardized assessment tools — PHQ-9 for depression, CAPS-5 or PCL-5 for PTSD, validated dissociation scales — should be used consistently. Adverse-event escalation protocols and emergency response procedures are foundational.

Provincial regulatory context for KAT training

Atomic answer: No single national framework governs KAT in Canada. Each province's physician college sets the rules for off-label ketamine prescribing, and the rules differ materially. Alberta has the most developed framework (CPSA accreditation + provincial PAPT licensing). Manitoba and British Columbia have published current guidance. Ontario, Saskatchewan, and several Atlantic provinces do not have ketamine-specific guidance. Clinicians training to deliver KAT must work within the rules of the province where they will practise. The summary table below reflects the regulatory landscape as of May 2026.

Important notice on ketamine off-label use: Racemic ketamine is approved by Health Canada as an anaesthetic agent (Schedule I, Controlled Drugs and Substances Act). Its use for psychiatric indications (treatment-resistant depression, PTSD, anxiety, chronic pain) is off-label and is not endorsed or prohibited by Health Canada. Off-label prescribing does not require Health Canada's Special Access Program; authorization is governed by your provincial physician college. Esketamine (Spravato®) is separately approved by Health Canada for treatment-resistant major depressive disorder in adults, in combination with an oral antidepressant, available only through the Janssen Journey™ Program. Provincial standards for ketamine-assisted psychotherapy are evolving; clinicians and training programs should verify current requirements with their own regulatory college before practice.

Already trained and ready to bring KAT into your practice? Explore the coordinated care program for clinical protocols, operational systems, and access to a network of trained clinicians.

CE credits, accreditation, and professional recognition

Continuing-education recognition for KAT training varies by regulator and by program. As of May 2026:

• MDPAC Psychotherapy Training Program (2025–2026): up to 65 RCPSC MOC Section 1 credits and up to 65 CFPC Mainpro+ credits — the clearest current dual-accredited Canadian program with psychedelic content. (Note: this is general psychotherapy training that includes ketamine/psychedelic content as a module, not a standalone KAT certification.)
• Numinus Practical Applications of Ketamine-Assisted Therapy: 3 CE hours by CPA, 50 CE hours by CCPA and OPQ, 50 by NBCC.
• Roots to Thrive Experiential KAT Training: 52 hours; not formally CE-accredited; practicum hours previously counted toward Vancouver Island University's PATGC, which was discontinued November 20, 2025.
• Field Trip Health PAT Training: explicitly not CE-accredited.
• Polaris Insight Center (US-based): APA-approved for psychologists; Canadian accreditation not confirmed.

After training: integrating KAT into your Canadian practice

Completing training is the first step toward delivering KAT in clinical practice. The next steps depend on the clinician's professional registration, the provincial regulatory rules, and the practice setting.

For clinicians working independently, the considerations include securing prescriber partnership (for non-prescribers), establishing facility compliance for the routes being delivered (IV facilities require provincial accreditation), implementing screening and intake protocols, documenting informed consent for off-label use, securing professional liability coverage that explicitly includes KAT, and arranging ongoing supervision for the first cohort of cases.

For clinicians joining or building a practice within an existing network, ATMA CENA's coordinated care program provides clinical protocols, operational systems, and access to a network of trained clinicians. Joining the coordinated care network requires completion of an ATMA CENA training pathway (Clinical or Prescriber) and is the structured route for integrating KAT into an existing or new practice within ATMA CENA's network.

ATMA CENA's clinics include the corporate locations in Edmonton and Calgary plus member clinics in Hamilton, Kitchener-Waterloo, London, Mississauga, Montreal, North Bay, Oakville, Sarnia, Saskatoon, Vaughan, Windsor, and Winnipeg.

Frequently asked questions

Is ketamine therapy training legal in Canada?

Yes. Training to deliver supervised ketamine-assisted psychotherapy is legal in Canada. Ketamine itself is a Health Canada-approved anaesthetic; its use for psychiatric indications is off-label and is regulated by provincial physician colleges rather than by Health Canada directly.

Do I need to be a physician to train in KAT?

No. Training is open to a range of registered mental-health professionals including registered psychotherapists (Ontario), permit-holding psychotherapists (Quebec), registered counsellors, registered psychologists, registered nurses, and registered social workers. Only physicians and nurse practitioners with controlled-substance prescribing authority can prescribe and administer the medicine itself; non-prescribers serve on multidisciplinary teams under prescriber oversight.

How long does KAT training take?

Time-to-completion varies by pathway and prior experience. The Foundations course is 14 hours of didactic content. The Applied Clinical Practice course (Clinical pathway) is 55 hours. The Prescribing & Oversight course (Prescriber pathway) is 40 hours. Supervised practicum and the optional KAT Immersive Experience add additional time. Many clinicians complete a full pathway over 6 to 18 months while continuing active practice.

What CE credits does ATMA CENA's KAT training carry?

Does ketamine require a Special Access Program (SAP) application?

No. Ketamine is an approved drug in Canada (anaesthetic indication) with an existing Drug Identification Number. Off-label psychiatric use does not require SAP. SAP applies only to drugs not marketed in Canada; for the psychedelic field, that means psilocybin and MDMA require SAP, but ketamine does not.

Can registered counsellors deliver ketamine therapy?

Counsellors cannot prescribe, dispense, or administer ketamine. Counsellors can deliver the psychotherapy components of KAT (preparation and integration counselling, therapeutic alliance, support during dosing sessions) within a multidisciplinary team led by a prescribing physician or nurse practitioner. BCACC and BCCSW have confirmed this scope for BC counsellors and social workers respectively.

What does experiential training in KAT involve?

Experiential training typically includes observation of a KAT session, co-facilitation under direct supervision, and (in some programs) the option for personal experiential exposure to a non-ordinary state. ATMA CENA's Ketamine-Assisted Therapy Immersive Experience is a 3-day in-person practicum offered to clinicians who choose to add it to their pathway.

How does KAT differ from ketamine infusion alone?

KAT integrates structured psychotherapy with the medicine across three phases: preparation, dosing-day support, and integration. Ketamine infusion alone delivers the medicine without structured psychotherapy. A peer-reviewed open-label trial found that adding 10 weeks of cognitive behavioural therapy following IV ketamine produced sustained response in 75 percent of ketamine responders at 8 weeks, compared with the typically transient response seen after ketamine alone [Wilkinson et al. 2017].

How much does KAT training cost in Canada?

Tuition varies by program. ATMA CENA's pathway-level cost (Foundations + Applied Clinical = $6,200 CAD for the Clinical pathway; Foundations + Prescribing & Oversight = $4,800 CAD for the Prescriber pathway). The optional KAT Immersive Experience is $2,400 CAD. For comparison, Numinus Practical Applications is $2,500 USD; Roots to Thrive Experiential KAT is $3,950 USD; Field Trip Health PAT is $1,500 CAD; CIIS Certificate (US) ranges $8,900–$9,400 USD. See the Psychedelic Therapy Training Cost in Canada page for detailed comparison.

What happens to clinicians who completed VIU's psychedelic-assisted therapy graduate certificate?

Vancouver Island University discontinued its Graduate Certificate in Psychedelic-Assisted Therapy on November 20, 2025. Continuing students have access to the program through August 31, 2026. New enrolees are not being accepted. Clinicians who were exploring that program may find ATMA CENA's pathways a Canadian-context alternative. ATMA CENA is not affiliated with VIU.

Apply, book an info call, or explore the course catalogue

For physicians considering the Prescriber pathway specifically, the Prescriber Pathway page details cardiovascular and neurological screening, ketamine titration, and SAP application authorship for psilocybin and MDMA where applicable. For non-prescribing therapists, the Clinical Pathway page covers direct delivery competencies.

Sources

1. Health Canada. Drug Product Database — Ketamine Hydrochloride Injection USP (DIN 02246796). https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=70996
2. Health Canada. Drug Product Database — Spravato (DIN 98903). https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98903
3. Health Canada (2022). Notice to stakeholders: Health Canada's expectations regarding risk-management measures for clinical trials involving psychedelic-assisted psychotherapy. https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/expectations-risk-management-measures-clinical-trials-psychedelic-assisted-psychotherapy.html
4. College of Physicians and Surgeons of Alberta (2026). Ketamine Prescribing, Administration and Oversight Expectations (March 2026). https://cpsa.ca/wp-content/uploads/2026/03/CPSA_Ketamine-Guidance_March-2026.pdf
5. CPSA. Psychedelic-Assisted Psychotherapy Facility Accreditation. https://cpsa.ca/facilities-clinics/accreditation/psychedelic-assisted-psychotherapy/
6. College of Physicians and Surgeons of Manitoba (2026). Ketamine: What Prescribers and Pharmacists Need to Know (January 2026). https://www.cpsm.mb.ca/news/ketamine-what-prescribers-and-pharmacists-need-to-know
7. College of Physicians and Surgeons of British Columbia (2025). Interim Guidance: Ketamine Administration via Intramuscular, Oral, Sublingual, Intranasal Routes (Version 1.3, August 2025). https://www.cpsbc.ca/files/pdf/IG-Ketamine-Administration-via-Intramuscular-Oral-Sublingual-Intranasal-Routes.pdf
8. CPSO. Prescribing Drugs. https://www.cpso.on.ca/Physicians/Policies-Guidance/Policies/Prescribing-Drugs
9. CPSS (2021). Position on Ketamine Off-Label Use (January 2021). https://www.cps.sk.ca/iMIS/Documents/For%20Physicians/Advisories%20and%20Positions/2021.01.19%20Ketamine%20off-label%20use%20CPSS%20position%20document.pdf
10. INESSS (2025). Parenteral ketamine for treatment-resistant depression in adults. https://www.inesss.qc.ca/en/publications/publications/publication/ketamine-pertinence-dans-la-depression-refractaire-aux-traitements-et-encadrement.html
11. CRPO. Psychedelic-Assisted Psychotherapy Resource. https://crpo.ca/resource-articles/psychedelic-assisted-psychotherapy/
12. CRPO. Practice Standard 6.2 Advertising. https://crpo.ca/practice-standards/business-practices/advertising/
13. College of Alberta Psychologists (2025). Practice Guideline: Psychedelic-Assisted Psychotherapy (June 2025). https://www.cap.ab.ca/Portals/0/adam/Content/fQCpza4q7EGXC_psrgnCvA/Link/Psychedelic-Assisted%20Psychotherapy%20-%20June%202025.pdf
14. Government of Alberta. Psychedelic Drug Treatment Service Provider Licensing. https://www.alberta.ca/psychedelic-drug-treatment-service-provider-licensing
15. BCCSW. Practice Guidance: Psychedelic-Assisted Psychotherapy. https://bccsw.ca/for-registrants/standards-scope-of-practice/practice-guidance/practice-guidance-document-for-registrants-psychedelic-assisted-psychotherapy/
16. KATA Canada. Practice Standards. https://katacanada.org/resources/practice-standards/
17. Kang, M.J.Y., Hawken, E. & Vazquez, G.H. (2022). The Mechanisms Behind Rapid Antidepressant Effects of Ketamine: A Systematic Review With a Focus on Molecular Neuroplasticity. Frontiers in Psychiatry, 13:860882. https://pubmed.ncbi.nlm.nih.gov/35546951/
18. Dean, R.L. et al. (2021). Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder. Cochrane Database of Systematic Reviews. https://pubmed.ncbi.nlm.nih.gov/34510411/
19. Alnefeesi, Y. et al. (2022). Real-world effectiveness of ketamine in treatment-resistant depression: A systematic review and meta-analysis. Journal of Psychiatric Research. https://pubmed.ncbi.nlm.nih.gov/35688035/
20. Chrenek, C., Duong, B., Khullar, A., McRee, C., Thomas, R. & Swainson, J. (2024). Use of ketamine for treatment-resistant depression: updated review of literature and practical applications to a community ketamine program in Edmonton, Alberta, Canada. Frontiers in Psychiatry. https://pubmed.ncbi.nlm.nih.gov/38260793/
21. Dore, J., Turnipseed, B., Dwyer, S. et al. (2019). Ketamine Assisted Psychotherapy: Patient Demographics, Clinical Data and Outcomes in Three Large Practices Administering Ketamine With Psychotherapy. Journal of Psychoactive Drugs, 51(2). https://pubmed.ncbi.nlm.nih.gov/30917760/
22. Yermus, R. et al. (2024). Ketamine-Assisted Psychotherapy in a Real-World Canadian Setting. Psychedelic Medicine, 2(2). https://pubmed.ncbi.nlm.nih.gov/40051583/
23. Wilkinson, S.T. et al. (2017). Cognitive Behavior Therapy for the Prevention of Relapse and Recovery of Response to Intravenous Ketamine in Treatment-Resistant Depression. Psychotherapy and Psychosomatics, 86(3). https://pubmed.ncbi.nlm.nih.gov/28490030/
24. Tsang, V.W.L., Tao, B., Dames, S., Walsh, Z., Kryskow, P. (2023). Safety and tolerability of group-based ketamine-assisted therapy. Therapeutic Advances in Psychopharmacology, 13. https://pubmed.ncbi.nlm.nih.gov/37256163/
25. Dames, S., Kryskow, P., Tsang, V.W.L., Argento, E. (2025). Roots to Thrive Ketamine-Assisted Therapy clinical model. Frontiers in Psychiatry. https://pubmed.ncbi.nlm.nih.gov/41058650/
26. Drozdz, S.J., Goel, A., McGarr, M.W. et al. (2022). Ketamine Assisted Psychotherapy: A Systematic Narrative Review of the Literature. Journal of Pain Research, 15. https://pubmed.ncbi.nlm.nih.gov/35734507/
27. Argento, E., Petker, T., Vig, J. et al. (2024). KAT therapist training: a qualitative study. PLoS One, 19(8). https://pubmed.ncbi.nlm.nih.gov/39208303/
28. Phelps, J. (2017). Developing Guidelines and Competencies for the Training of Psychedelic Therapists. Journal of Humanistic Psychology, 57(5). https://journals.sagepub.com/doi/10.1177/0022167817711304
29. Hartogsohn, I. (2018). The Meaning-Enhancing Properties of Psychedelics. Frontiers in Neuroscience. https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2018.00129/full
30. Gorman, I. et al. (2021). Psychedelic Harm Reduction and Integration: A Transtheoretical Model. Frontiers in Psychology, 12:645246. https://www.frontiersin.org/journals/psychology/articles/10.3389/fpsyg.2021.645246/full
31. Brennan, W. & Belser, A.B. (2022). EMBARK: A Transdiagnostic, Trans-Drug PAP Model. Frontiers in Psychology, 13:866018. https://www.frontiersin.org/journals/psychology/articles/10.3389/fpsyg.2022.866018/full
32. Popova, V. et al. (2019). Esketamine nasal spray for TRD: TRANSFORM-2 Phase 3. American Journal of Psychiatry. https://pubmed.ncbi.nlm.nih.gov/31109201/
33. Daly, E.J. et al. (2019). Esketamine relapse prevention Phase 3. JAMA Psychiatry. https://pubmed.ncbi.nlm.nih.gov/31166571/
34. Hovda, S. et al. (2024). Ketamine safety: systematic review. Journal of Affective Disorders. https://pubmed.ncbi.nlm.nih.gov/37875227/
35. Chan, K.W.Y. et al. (2022). Ketamine-associated uropathy meta-analysis. Hong Kong Medical Journal. https://pubmed.ncbi.nlm.nih.gov/36464318/
36. Dames, S., Watler, K., Kryskow, P. et al. (2024). Firsthand experience as a training element for PAT practitioners. Psychedelic Medicine. https://pmc.ncbi.nlm.nih.gov/articles/PMC11658659/

Related articles in this cluster

• Psychedelic Therapy Training in Canada
• Psilocybin Therapy Training in Canada
• MDMA-Assisted Therapy Training in Canada
• Psychedelic Therapy Training for Physicians
• Psychedelic Therapy Training for Counsellors
• Psychedelic Therapy Training for Psychotherapists
• Psychedelic Therapy Training for Psychologists
• Psychedelic Therapy Training Cost in Canada
• Which Psychedelic Therapy Training Pathway Is Right for Me?
• How to Become a Psychedelic Therapist in Canada
• How to Get Psychedelic Therapy Certification in Canada

Last updated: 2026-05-05. Article is reviewed every 6 months.